Bramley Kyle, Pisani Margaret A, Murphy Terrence E, Araujo Katy L, Homer Robert J, Puchalski Jonathan T
Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut.
Claude D. Pepper Older Americans Independence Center at Yale, Program on Aging, Yale University School of Medicine, New Haven, Connecticut.
Ann Thorac Surg. 2016 May;101(5):1870-6. doi: 10.1016/j.athoracsur.2015.11.051. Epub 2016 Feb 22.
Endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) is important in the evaluation of thoracic lymphadenopathy. Reliably providing excellent diagnostic yield for malignancy, its diagnosis of sarcoidosis is inconsistent. Furthermore, TBNA may not suffice when larger "core biopsy" samples of malignant tissue are required. The primary objective of this study was to determine if the sequential use of TBNA and a novel technique called cautery-assisted transbronchial forceps biopsy (ca-TBFB) was safe. Secondary outcomes included sensitivity and successful acquisition of tissue.
The study prospectively enrolled 50 unselected patients undergoing convex-probe EBUS. All lymph nodes exceeding 1 cm were sequentially biopsied under EBUS guidance using TBNA and ca-TBFB. Safety and sensitivity were assessed at the nodal level for 111 nodes. Results of each technique were also reported for each patient.
There were no significant adverse events. In nodes determined to be malignant, TBNA provided higher sensitivity (100%) than ca-TBFB (78%). However, among nodes with granulomatous inflammation, ca-TBFB exhibited higher sensitivity (90%) than TBNA (33%). On the one hand, for analysis based on patients rather than nodes, 6 of the 31 patients with malignancy would have been missed or understaged if the diagnosis were based on samples obtained by ca-TBFB. On the other hand, 3 of 8 patients with sarcoidosis would have been missed if analysis were based only on TBNA samples. In some patients, only ca-TBFB acquired sufficient tissue for the core samples needed in clinical trials of malignancy.
The sequential use of TBNA and ca-TBFB appears to be safe. The larger samples obtained from ca-TBFB increased its sensitivity to detect granulomatous disease and provided adequate specimens for clinical trials of malignancy when specimens from needle biopsies were insufficient. For thoracic surgeons and advanced bronchoscopists, we advocate ca-TBFB as an alternative to TBNA in select clinical scenarios.
支气管内超声(EBUS)引导下经支气管针吸活检(TBNA)在评估胸部淋巴结病变中具有重要意义。它能可靠地为恶性肿瘤提供较高的诊断率,但其对结节病的诊断并不一致。此外,当需要获取更大的恶性组织“核心活检”样本时,TBNA可能并不足够。本研究的主要目的是确定序贯使用TBNA和一种名为烧灼辅助经支气管钳夹活检(ca-TBFB)的新技术是否安全。次要结果包括敏感性和成功获取组织。
该研究前瞻性纳入了50例未经过筛选的接受凸阵探头EBUS检查的患者。所有直径超过1cm的淋巴结在EBUS引导下依次采用TBNA和ca-TBFB进行活检。对111个淋巴结的节点水平进行安全性和敏感性评估。同时也报告了每位患者每种技术的结果。
未发生显著不良事件。在确诊为恶性的淋巴结中,TBNA的敏感性(100%)高于ca-TBFB(78%)。然而,在伴有肉芽肿性炎症的淋巴结中,ca-TBFB的敏感性(90%)高于TBNA(33%)。一方面,基于患者而非淋巴结进行分析时,如果诊断仅基于ca-TBFB获取的样本,31例恶性肿瘤患者中有6例可能会被漏诊或分期过低。另一方面,如果仅基于TBNA样本进行分析,8例结节病患者中有3例可能会被漏诊。在一些患者中,只有ca-TBFB获取了足够的组织用于恶性肿瘤临床试验所需的核心样本。
序贯使用TBNA和ca-TBFB似乎是安全的。ca-TBFB获取的更大样本提高了其检测肉芽肿性疾病的敏感性,并且在针吸活检样本不足时为恶性肿瘤临床试验提供了足够的标本。对于胸外科医生和高级支气管镜检查医师,我们提倡在特定临床场景中使用ca-TBFB替代TBNA。